Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Aug 2026 | FROM AKERO THERAPEUTICS
Efruxifermin in metabolic dysfunction-associated steatohepatitis: phase 2b results and implications for ongoing phase 3 trials
Aug 2026 | FROM AKERO THERAPEUTICS
Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH
